HER2-positive metastatic breast cancer in Kazakhstan

Inclusion Criteria

• Inclusion Criteria:
• - Patients with HER2-positive mBC who are receiving or have started any anti-HER2 therapy (except for trastuzumab deruxtecan) at the time of inclusion
• - The diagnosis of mBC was established between the 1st January 2022 to 31st December 2023
• - Patients with the availability of at least 24 months of follow-up data (from the date of mBC diagnosis) in the medical records at the participating site, unless patient died/moved or refused the therapy within the first 24 months of diagnosis
• - Age ≥18 years at the time of inclusion
• Exclusion Criteria:
• - Presence of other malignancies within the period from mBC diagnosis until the timepoint of data collection
• - Patients received trastuzumab deruxtecan
• - The participation in any interventional trial within period since diagnosis until the end of study